A case report of anti-P200 pemphigoid following COVID-19 vaccination

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

“…Panepidermal necrosis along with a significant sparse lymphocytic infiltrate, 47,57,113,114 suprabasal epithelial splitting, and C3 depositions were noted in the histopathologic evaluation. 115–121 Furthermore, papulosquamous exanthema (cutaneous lupus erythematous) was observed after vaccination; vacuolar interface or spongiotic dermatitis, significant lymphocytic and eosinophilic infiltrates, and slight deposition of mucin into dermis were detected in microscopy. 122–126…”

“…Panepidermal necrosis along with a significant sparse lymphocytic infiltrate, 47,57,113,114 suprabasal epithelial splitting, and C3 depositions were noted in the histopathologic evaluation. [115][116][117][118][119][120][121] Furthermore, papulosquamous exanthema (cutaneous lupus erythematous) was observed after vaccination; vacuolar interface or spongiotic dermatitis, significant lymphocytic and eosinophilic infiltrates, and slight deposition of mucin into dermis were detected in microscopy. [122][123][124][125][126] A histopathologic study of a delayed large local reaction in a middle-aged woman revealed extensive lymphohistiocytic infiltrates with CD3 + (including CD8 + and CD4 + ) T cells and some eosinophils.…”

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

“…In the new onset group, BP patients with limited involvement were treated with topical corticosteroids, while those with more extensive involvements received a variety of systemic immunomodulators, including corticosteroids, doxycycline, nicotinamide, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, dapsone, colchicine, or hydroxychloroquine [5,6,14,15,28,31,32,35,38,39,[42][43][44][45]49,51,53,56,[70][71][72][73]75,77,82,86,87,92,93]. DPP-4 inhibitors were suspended in patients using these medications [34,44,45,48].…”